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Abstract
Background: Neonatal screening for 21 hydroxylase deficiency is designed to detect classical form of congenital
adrenal hyperplasia (CAH). It is still unclear whether newborns who result false positives at neonatal screening
might later develop signs of androgen excess. The aim of this study is to verify whether a slightly elevated 17-OHP
at newborn screening is a predictive factor for premature pubarche.
Methods: We evaluated all infants born between 2001 and 2014 with premature pubarche. In case of increased
bone age, they were submitted to functional tests to find out the cause of their symptoms. Their 17-OHP values at
newborn screening for CAH were reconsidered.
Results: We identified 330 patients (269 females, 61 males) with premature pubarche. All these children had a
normal 17-OHP at newborn screening with the exception of a child, born preterm and not affected by CAH.
Conclusions: An elevated 17-OHP at newborn screening is not a predictive factor for premature pubarche. A likely
cause of increased 17-OHP level at screening is an immaturity of adrenal gland or a neonatal stress. Therefore a
strict follow up of these neonates during childhood is not necessary.
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Background
Since 2001 a neonatal screening program for congenital ad-
renal hyperplasia (CAH), based on 17-hydroxyprogesterone
(17-OHP) assay on filter paper-dried blood spots, has been
instituted in North-Eastern Italy. It aims to obtain an early
identification of the newborns affected by classic form of 21
hydroxylase deficiency (21-OHD), and consequently to
prevent both potential life-threatening shock due to salt
waste, especially in male newborns, and incorrect sex as-
signment in affected girls with inappropriate virilization
[1–4]. Nevertheless, the real sustainability of this neonatal
screening remains debated. Some studies have in fact
underlined the high rate of recall that the neonatal screen-
ing determines, especially in preterm infants, and pointed
out the psychological and financial costs resulting in these
recalls, which entail a visit to a pediatrician and serum
confirmatory tests [5, 6]. In order to prevent these draw-
backs, we have previously suggested to avoid any further
investigations in newborns who result positive at CAH
neonatal screening and do not present classic form of
CAH, when serum 17-OHP levels decrease over time after
birth [7]. However, screening procedure does not allow to
identify babies with non-classical 21-OHD, since basal
serum 17-OHP levels are often in the normal range in pa-
tients with this form of disease [1, 8–11]. Consequently, it
is recommended to perform other more specific confir-
matory assessments, namely functional tests, if further
symptoms, such as premature pubarche, acne, hirsutism,
appear [1, 3, 7]. In fact, it is still unclear whether a new-
born with a slightly elevated 17OHP levels at neonatal
screening may later develop premature pubarche or other
symptoms of androgen excess. Furthermore, a precocious
identification of premature pubarche is useful since it may
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reduce related complications like obesity and insulin re-
sistance [12, 13].
Hence, the aim of this study is to verify whether an
elevated 17-OHP at newborn screening is a predictive
factor for premature pubarche.
Methods
We enrolled in this study all infants born between 2001
and 2014 that were later referred to the Pediatric Endo-
crinology Division of Verona Hospital, Italy, for prema-
ture pubarche defined as development of pubic hair
before the age of 8 years in girls or 9 years in boys.
All patients were evaluated in order to determine their
weight, height, BMI, and pubertal development using
Tanner and Whitehouse method [14]. For boys, testicu-
lar volume was assessed using a Prader’s orchidometer.
All children underwent radiography to determine bone
age, evaluated with Greulich and Pyle method [15]. In
children with advanced bone age, blood tests were per-
formed to measure serum 17-OHP, cortisol, testosterone,
ACTH, DHEAS, Δ4-androstenedione. Moreover, gesta-
tional age (GA), birth weight (BW), birth length (BL)
and result of 17-OHP screening were reconsidered.
ACTH stimulation test was performed using soluble
Synacthen 250 mg intravenously for all children with in-
creased bone age (ratio of bone age to chronological age
greater than 1). Serum levels of 17-OHP and cortisol
were evaluated at baseline and after 60 min. Data were
analyzed using Maria New nomogram [16].
GnRH-analogous (GnRH-a) stimulation test was per-
formed in patients with associated signs of precocious
puberty (premature thelarche for girls or testicular vol-
ume > 4 mL for boys), administering 0.1 mg of GnRH-a
(Triptorelin) subcutaneously after overnight fasting.
Serum levels of FSH, LH, estradiol and testosterone were
measured at baseline and 4 h after the injection.
Serum 17-OHP was assayed by radioimmunoassay
(DSL-5000 Active 17α-OH Progesterone Coated-Tube
Radioimmunoassay, Diasorin Spa Italia). Assay sensitiv-
ity was 0.01 ng/dL, whereas intra- and inter-assay coeffi-
cients of variation were both 9.0%.
Serum total testosterone, ACTH, cortisol, Δ4-
androstenedione, DHEAS, estradiol, FSH and LH were
measured by a solid-phase, competitive chemilumines-
cent enzyme immunoassay (Immulite 2000, Siemens
Healthcare Diagnostic, Deerfield, IL, USA). Analytical
sensitivity was 0.05 mIU/mL (0.5 nmol/L) for total
testosterone, 1.1 pmol/L for ACTH, 0.2 μg/dL for
cortisol, 1 nmol/L for Δ4-androstenedione, 0.3 μg/dL
for DHEAS, 0.1 mIU/mL for FSH, 0.05 mIU/mL for
LH and 15 pg/mL for estradiol.
Intra-assay and inter-assay coefficients of variation
were 11.7 and 13.0% respectively for testosterone, 9.5
and 10.0% respectively for ACTH, 7.4 and 9.4% respect-
ively for cortisol, 9.3 and 12% respectively for Δ4-
androstenedione, 4.1 and 6.3% respectively for DHEAS,
2.9 and 4.1% respectively for FSH, 3.6% and 6.7 respect-
ively for LH, 11.7 and 13% respectively for estradiol.
Neonatal screening for CAH was performed using dried
blood spots on filter paper. The blood sampling was col-
lected between 48 and 72 h of life. 17-OHP was determined
by immunofluorometric assay (Kit DELFIA Neonatal 17-
hydroxyprogesterone Kit; Perkin Elmer, Wallac Oy, Turku,
Finland).
The study was conducted in compliance with the
terms of the Helsinki II Declaration. In Italy, this type of
retrospective study do not require Institutional Review
Board/Institutional Ethics Committee approval in order
to publish the results. Written informed consent was
obtained from the parents of each patient.
All statistical analyses were performed using software R.
Comparisons between groups were performed using
Student’s t-test or the Wilcoxon test, when appropriate.
Data are expressed as numbers with frequency, median
plus range, or mean± SD, as appropriate. Statistical signifi-
cance was considered when p-values were less than 0.05.
Results
We identified 330 patients with premature pubarche,
269 females (81.5%) and 61 males (18.5%). Their mean
age at diagnosis was 7.3 ± 1.8 years. The auxological data
of our population are represented in Table 1. Twenty
percent of them were premature with GA < 37 weeks
and the 13.7% had low body weight (< 2500 g). The-
larche in association to pubarche was present in the 31%
of girls, while only 3% of male patients had an enlarge-
ment of testicular volume. Hundred and seventy-two
patients (51.5%) presented advanced bone age. In female
patients bone age was 1.3 ± 1.0 years increased com-
pared to anagraphic age, in boys the increase of bone
age was of 1.4 ± 1.0 years. These 172 patients underwent
blood exams as shown in Table 2.
Table 1 Neonatal and auxological data at diagnosis. Data are
expressed as mean ± standard deviation and range (min-max) in
the brackets
Patients
GA (weeks) 38.5 ± 2.5 (25.0–42.0)
BW (g) 3059 ± 650 (787–5000)
BL (cm) 49.5 ± 2.8 (25.0–55.0)
Age at diagnosis (years) 7.3 ± 1.8 (0.4–10.3)
wheight SDS at diagnosis 3.1 ± 2.2 (−1.6–11.4)
height SDS at diagnosis 2.0 ± 1.2 (−1.7–5.4)
BMI SDS at diagnosis 2.1 ± 2.1 (−2.2–9.9)
GA Gestational Age, BW Birth Weight, BL Birth Length
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Figure 1 represents the etiology of pubarche identified
in our cohort on the basis of ACTH test and GnRH-a
test results (data not shown). Moreover, 25 children (24
females and 1 male) presented levels of 17-OHP at the
ACTH test compatible with a heterozygous condition
for 21-OHD.
Figure 2 represents the 17 OHP levels evaluated at
neonatal screening of all patients with premature pub-
arche. All 3 patients with late onset CAH had normal
17-OHP screening values. Only one patient (born pre-
term at 28 weeks of GA and with BW of 1010 g) pre-
sented borderline values of 17-OHP at newborn
screening; however, he was not affected by CAH but
only by an idiopathic premature pubarche.
Discussion
To our knowledge, this is the first study analyzing the
relation between premature pubarche and the 17-OHP
level at newborn screening for CAH.
Premature pubarche is not rare and usually appears as
secondary condition of an early isolated maturation of
adrenal gland [17–19]. In some patients, adrenal andro-
gens may be moderately increased for chronological age,
although in the normal range for their stage of pubic
hair, in others androgen levels are normal, but some
Authors have suggested an increased peripheral sensitiv-
ity to androgens [17]. Nevertheless, the diagnosis of pre-
mature pubarche is a diagnosis of exclusion. In fact, in
the 6.6% of our patients, premature pubarche was asso-
ciated with precocious puberty, since all these children
presented not only premature pubarche, but also some
initial pubertal signs. Moreover, late-onset CAH, other
rare mild errors of steroidogenesis and virilizing adrenal
or gonadal tumors must all be ruled out [17].
Within a diagnostic frame, it remains controversial
which patients should be submitted to ACTH stimula-
tion test. Some Authors recommend to submit patients
to this test as the ratio between bone age and statural
age exceeds 1, or whenever androgen levels are elevated,
or, finally, in case of bone age advancement, cystic acne
or other signs of systemic virilisation detection [17]. We de-
cided to perform the ACTH test whenever the ratio of bone
age to chronological age was greater than 1 and, on this
basis, we identified 3 children affected by late-onset CAH
(1.7%). None of our cohort presented virilising tumors.
The remaining children (92.5% of total cohort) re-
sulted affected by idiopathic premature pubarche.
Among them, the 63.5% presented elevated DHEAS
levels. Although DHEAS is a weak androgen, it is a sub-
strate for the synthesis of more potent androgens, and
levels of DHEAS superior than 40–50 μg/dL are associ-
ated with the appearance of a pubarche [17, 19, 20]. In
these patients premature pubarche may originate from a
functional adrenal hyperandrogenism of unknown aeti-
ology, perhaps due to hyperplasia of the zona reticularis
of the adrenal gland. In the other 36.5% the appearance
of the premature pubarche may be related to the above
mentioned increased peripheral sensitivity to normal
androgen levels.
The prevalence of CAH in our cohort of children with
premature pubarche is comparable with previous data,
which have estimated it to a range from 0 to 40% [9, 20–24].
Yet, after ACTH stimulation test, 25 children (14.5%)
showed level of 17-OHP compatible with a heterozygous
condition. It is well known that patients with premature
pubarche, hirsutism and early puberty may present a 21-
hydroxylase mild deficiency due to the heterozygous status
[25]. As a matter of fact, a high percentage of sub-
jects unaffected by CAH but presenting hyperandro-
genic signs carries mutations of the CYP21A2 gene in
heterozygous state [26–28]. Whereas some Authors
report similar risk for mutation carriers and wild type
subjects [29, 30], others evidenced an association be-
tween clinical signs of hyperandrogenism and the het-
erozygous condition, especially in subjects carrying
the mutation V281 L [31, 32]. A dominant-negative
effect of this mutant allele on the wild type has been
described, reducing the enzyme activity with the con-
sequence of a higher risk of symptoms due to andro-
gen excess [31]. Although we did not submit our 25
children to genetic analysis, their 17-OHP levels com-
patible with heterozygous condition would confirm an
association between heterozygous condition and the
presence of premature pubarche. The real mechanism
behind this association still remains unknown.
With the exception of one child born preterm, all
patient with premature pubarche, including the 3 non
classical CAH patients, presented 17-OHP levels in the
reference range at newborn screening. The data pre-
sented in this manuscript show that an elevated 17-OHP
at newborn screening is not a sign of increased risk of
premature pubarche. As above mentioned, neonatal
screening for CAH is not designed to detect non-
Table 2 Laboratoristic exams. Data are expressed as mean ±
standard deviation and range (min-max) in the brackets
Patients
Cortisol basal (μg/dL) 11.3 ± 8.0 (1.6–63.0)
Cortisol peak (μg/dL) 26.4 ± 5.5 (1.0–42.9)
ACTH (pg/mL) 28.5 ± 42.2 (6.2–373.0)
17 OHP basal (ng/dL) 1.3 ± 2.4 (0.1–18)
17 OHP peak (ng/dL) 5.2 ± 11.6 (1.1–110.0)
Testosterone (ng/dL) 20.3 ± 6.8 (0.3–39.6)
Testosterone peak (ng/dL) 22.3 ± 14.7 (2.1–72.8)
Δ4-androstenedione (ng/mL) 0.6 ± 0.5 (0.3–3.0)
DHEAS (μg/dL) 74.6 ± 48.8 (0.4–291.0)
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classical form of the disease, since basal serum 17-OHP
levels are often in the normal range in patients with this
form of disease [1, 8–11]. Their identification might
require a lower cut-off value, with a significant increase
in false-positive recalls and substantial rise in the cost:be-
nefit ratio [33]. But is it necessary to submit asymptomatic
neonates with only slightly increased serum 17-OHP
levels to complete exams in order to exclude middle forms
of CAH, which in neonatal period may not require any
treatment but only an adequate follow-up over time? In a
previous manuscript, we concluded that no further inves-
tigations are necessary in newborns with a positive scree-
ning test if their serum 17-OHP levels decrease, and we
suggested to make other confirmatory tests only later on,
if further symptoms appear [7]. Other Authors have
suggested an annual follow-up by paediatric endocri-
nologist in order to check growth rate and signs of CAH
[1, 34, 35]. Our data permit not to recommend a periodic
endocrinologist follow up for these newborns; further
endocrinological investigations being necessary only if
symptoms appear during childhood.
The major drawback of neonatal screening for 21-
OHD are the high false-positive rate and the low positive
predictive value, mainly among preterm, low BW and ill
neonates [4, 36–38]. In particular, in France the effi-
ciency of routine 21-OHD screening resulted very low in
Fig. 1 Etiology of premature pubarche in our cohort
Fig. 2 Mean 17 OHP levels at neonatal screening of patients with premature pubarche, depending on their etiology (p > 0.05)
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preterm neonates, therefore French Authors suggested
to interrupt the screening in these newborns [6]. How-
ever, to reduce the false-positive rate, other screening
programs have established 17-OHP cut-off levels in rela-
tion to GA [36, 39–41] or BW [42–44]. We also used a
cut-off associated to GA [45]. The only child with idio-
pathic premature pubarche presenting elevated 17-OHP
at newborn screening resulted, in fact, unaffected by
CAH; however, he was born preterm (28 weeks of GA),
and, as well known, increased 17-OHP levels are com-
mon in preterm and low BW infants [36, 37, 46]. Since
the expression of the enzyme 11-β-hydroxylase physiolo-
gically appears with some delay [47], it is above all pre-
mature newborns with a GA of less than 31 weeks that
have elevated screening 17-OHP levels without inborn
errors of steroid biosynthesis [48]. In a previous study,
we have hypothesized that a low 21-hydroxylase enzym-
atic function might cause the elevated 17-OHP level evi-
denced at screening and we have affirmed that this
enzymatic immaturity might also be present in term ba-
bies [7]. Other factors that may contribute to increase
the 17-OHP level at birth are neonatal jaundice or neo-
natal disease. In fact, hyperbilirubinaemia may contrib-
ute to higher 17-OHP values due to the effect of
dehydration on blood concentration [49], and neonatal
stress may increase ACTH and 17-OHP levels [41].
Conclusions
In conclusion, we exclude that an elevated 17-OHP evi-
denced in babies unaffected by classical 21-OHD at new-
born screening might be a sign of future premature
pubarche. The main identified causes of increased 17-OHP
levels at birth remain an immaturity of adrenal gland and/
or a neonatal stress. Consequently, a strict follow up of
these infants during childhood is not necessary.
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